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a  b  s  t  r  a  c  t
The  consumer  exposure  to the  vast  majority  of  cosmetic  products  is  limited  to dermal  contact.  Even
spray applications  tend  to  be  topically  exposed  to  skin  or hair.  Besides  this  skin  contact,  spray  products
require  additional  considerations  in regard  to potential  inhalation  for  building  a robust  and  reliable  safety
assessment.
Over the  years,  cosmetic  industry  developed  prediction  models  for the  best  estimate  of  inhalation
exposure  combining  data  from  computer  simulation  programs  available  in  the  market,  individual  real
measured  data  and  last  but not  least  the  experience  from  the  market.  Such  attempt  is driven  by  the
toxicological  proﬁle  of  individual  used  ingredients.  The  focus  of  this  review  is on  the determination
of  inhalation  exposure,  and  the  derivation  of safe  exposure  levels  for  cosmetic  spray  products.  Many
of the  methods  employed  to  ensure  product  safety  of  cosmetic  sprays  in  accordance  with  the  general
requirements  of  the  EC  Cosmetics  Directive  are  based  on  industry  experience  which  are  not  necessarily
consistent  across  companies.This  paper  presents  an approach  to compile  common  principles  for risk  assessment  and  thus  contribute
to  standardisation  of safety  assessment  methodologies  utilized  for spray  product  evaluation  without
interfering  with  the  ﬂexibility  of the  individual  safety  assessor.  It  is  based  on  the  experience  within
the  author’s  companies  and  may  be  useful  as  a  support  document  as well  for  SME  (Small  and  Medium
Enterprises)  companies  safety  assessors.  In  this  respect  it can  be  seen  as  one  fundamental  step  in  a  tiered
approach of  cosmetic  spray  safety  evaluation.© 2011 Elsevier Ireland Ltd. 
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. Introduction
.1. Legal framework of cosmetic spray safety evaluation
Cosmetic spray products fall under the general requirements of
he EC Cosmetics Directive 76/768 regarding the safety of cosmetic
roducts, including the obligation to conduct a safety assessment
rior to introducing products into the market. This directive will be
eplaced stepwise by the new EC Cosmetics regulation 1223/2009
so called Recast, European Parliament and Council, 2009). Under
oth regulations, the toxicological proﬁle of all used ingredi-
nts and detailed knowledge of the product-speciﬁc exposure are
equired as fundamental for the safety assessment.
State-of-the-art concepts for the safety assessment of products
ith intentional exposure of skin, mucous membranes or the oral
avity have been described elsewhere (Mildau et al., 2007; Rossow
t al., 2005; SCCS, 2010; Mildau and Huber, 2010). Therefore, this
eview will focus on inhalation risk assessment only. Recently dis-
ussed new concepts in regulatory toxicology, such as the threshold
f toxicological concern (TTC) or the “point of departure” replacing
he no-observable-effect-level are outside of the scope of this arti-
le, but could eventually extend to safety assessment of sprays in
he future.
Based on the variability of how consumer use cosmetic spray
roducts, regulatory and scientiﬁc experts have developed a num-
er of models for quantitative exposure assessment. Several of
hese models are often based on unpublished data and are not
ormally harmonised within the cosmetics industry.
In 2010 the SCCS published a ﬁrst opinion taking into account
nhalation exposure evaluating the risk of dihydroxyacetone for self
anning products applied in spray cabines (SCCS/1347/10, 2010).
n broad ranges the SCCS Opinion is in line with the approach
escribed in this manuscript and as is currently used from major
arts of the cosmetic industry.
The intention of this paper is to propose some basic methodolog-
cal approaches and procedures in order to facilitate a harmonised
nd transparent safety assessment of cosmetic sprays. This paper
s not intended to be a binding industry standard but a recom-
endation to use these tools in the sense of a Weight-of-Evidence
pproach (WoE) when conducting the safety assessment.
In order to assess the safety of cosmetic spray products, this
aper outlines the major steps that need to be followed including
1) understanding exposure either by modelling or by mea-
urement, (2) understanding systemic and local exposure of the
espiratory tract and (3) using data on local toxicity and systemic
oxicity to establish margins of safety (MoS) and/or margins of
xposure (MoE) needed for the ﬁnal risk assessment.
.2. Description of cosmetic sprays
Cosmetic products used for spray applications are generally
omposed of the cosmetic product formulation, often containing
he active ingredient(s), and an appropriate solvent. Such com-
osition is ﬁlled in pressure resistant containers equipped with
roduct speciﬁc spray nozzles. For propellant driven spray applica-
ions, pressurised propellant mix  is ﬁnally added. In case of pump
prays, often creating less ﬁne aerosols, propellants are excluded.
prayed or vaporised products generate aerosols that can result in . . . .  . . .  . . . . .  .  .  . .  .  . . . . .  . .  . . . . . . .  .  . . . .  . . .  .  . . .  . . .  .  .  . . . . .  .  .  .  .  .  . . . . . . . . . .  .  . .  .  . 103
potential inhalation exposure of consumers using the product. As
those products with propellant producing foam or soft gels are not
suspected to emit inhalable aerosol, they are excluded from our
further discussion.
As deﬁned by the German MAK  commission, aerosols are mul-
tiphase systems of particulate solids or liquids dispersed in gases
such as air (Commission for the Investigation of Health Hazards of
Chemical Compounds in the Work Area (MAK  commission, 2010)).
Aerosols include dusts, fumes and mists. Dusts consist of particles of
solid matter generated by a mechanical process, or particles which
have been agitated and dispersed in gases. Fumes are dispersions of
very ﬁnely distributed solid matter in gases. They arise from ther-
mal  processes (e.g., welding fumes, metal (oxide) fumes, soot and
ﬂue ash) or chemical processes (e.g., the reaction of ammonia with
hydrogen chloride). Mists are ﬁnely divided liquid droplets of a sub-
stance or mixture suspended in air with sizes generally ranging
from 2 m to 100 m.  They arise during nebulisation of liquids,
during condensation from the vapour phase and during chemical
processes (e.g., oil mist, hydrogen chloride in damp air).
2. Assessment of inhalation exposure
2.1. Measuring particle size
Due to the anatomical construction of the respiratory tract, with
a brighter lumen in the upper trachea and very small ones in the
alveolar region, particle size of aerosol is a relevant parameter for
the distribution of substances in compartments of the respiratory
tract. The ﬁnal particle size of a product aerosol is determined by
the used ingredients and packaging details (e.g., spray nozzle, can
size, etc.). Aerosols can consist of a wide spectrum of particle sizes,
i.e. larger particle sizes (>10 m),  exposure to which is limited to
the upper respiratory tract and tracheobronchial tree, but also res-
pirable particle sizes (<10 m)  which can reach deep lung regions
(U.S. Department of Labor, MSHA, 2006).
Understanding of particle size distribution is essential for risk
assessment since there is broad consensus in the scientiﬁc com-
munity for the following assumptions:
• Signiﬁcant absorption of inhaled substances can occur in all parts
of the respiratory tract.
• Only droplets/particles with an aerodynamic diameter of less
than 10 m are considered to be respirable (Heyder et al., 1986),
i.e. reaching the deeper lung (very conservative assumption, 5 m
often described as threshold for particles which can reach the
alveoli (Commission for the Investigation of Health Hazards of
Chemical Compounds in the Work Area, 2010).
• Droplets/particles with an aerodynamic diameter of >15 m
are deposited almost exclusively extrathorically (nose, mouth,
throat) (Commission for the Investigation of Health Hazards
of Chemical Compounds in the Work Area, 2010), and healthy
humans will clear particles >7 m within 24 h from the tracheo-
bronchial compartment (Phalen and Oldham, 2006; Commission
for the Investigation of Health Hazards of Chemical Compounds
in the Work Area, 2010; Heyder et al., 1986; Federal Ofﬁce of
Public Health et al., 2009).
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as default data and extrapolated to other product types. Table 1
shows conservative default data on calculated daily exposure based
Table 1
Consumer application of aerosols. Results of recent studies.
Material Calculated
daily exposurea
[g/day]
Reference
Deodorant spray
(ethanol-based);
Deodorant spray
(not
ethanol-based)
1.43
0.69
SCCS (2010)
Hair spray, propellant gas 10 European Commission (1996)*maybe swallowed, contributes to total e
Fig. 1. Exposure and de
The most important aspects of deposition of inhaled particles
re shown in Fig. 1.
Typically, propellant gas sprays may  produce proportionate
espirable particles or droplets <10 m particle size (Bremmer
t al., 2006a; Eickmann, 2007a),  whereas pump sprays emit larger
roplets in a non-respirable range >10 m particle size. As men-
ioned above the particle/droplet size distribution is complex and
epends on product formulation and the technical details of the
pplicator. Thus, independent of the spray category, the parti-
le/droplet size spectrum can be modiﬁed in order to generate an
ptimized particle size distribution.
Typically, the mean diameter of primary droplets of a pump
pray is in the range of 70 m diameter while <1% is in the res-
irable range (unpublished industry data). Irrespective of the spray
eneration method, it is advisable to measure particle size distri-
ution and other aerosol characteristics and their time-dependent
hange, including agglomeration, sedimentation, and ageing effects
n order to make a thorough safety assessment.
Common methods of particle size measurement include, e.g.,
aser diffraction, use of the cascade impactor and time of ﬂight spec-
roscopy, but droplets can change due to ageing processes during
he ﬂight phase so care must be taken when analysing measured
ata. Droplet diameter may  decrease by evaporation of volatile con-
tituents. Droplets may  disperse after collision with solid surfaces,
hey may  aggregate, and deposit on solid surfaces. Therefore, any
pray pattern is subject to constant changes, and the interpretation
nd application of any such analytical data to the safety assessment
ust be carried out keeping in mind the limitations of accuracy and
pplicability of such data. Furthermore, the setting of product- and
ethod-speciﬁc parameters in the establishment of such analytical
ethods requires great experience and well trained personnel.
A detailed overview on particle size measurement methods is
iven in the guidance document of the European Aerosol Associa-
ion FEA (FEA European Aerosol Federation, 2009).
.2. Approaches to calculate exposure
To prepare a proper safety assessment for spray products the
est knowledge on the inhalation exposure under intended use
onditions should be available or estimated.
Real time measurements of speciﬁc product exposure represent
he gold standard, but need complex and extensive study designs.
ore simple mathematical approaches taking into account worst
ase defaults can be used as a ﬁrst step in a tiered approach for
xposure assessment.ure 
on of inhaled particles.
Easily, the concentration of any ingredient in the ambient air
can be calculated on the basis of the worst-case estimation of the
applied amount, duration of application as well as the distribution
volume, e.g., the volume of a standard bath room. By using con-
servative defaults (see below) the calculation of the exposure will
overestimate the real situation of human exposure. A clear advan-
tage of this approach is that a safety assessment may  be rapidly
performed and is independent of extensive measurements.
In those cases where a risk assessment on the basis of such an
initial conservative procedure does not yield a sufﬁcient safety mar-
gin, a reﬁned exposure assessment needs to be conducted. Relevant
data that reﬂect actual application situations may  be generated
by measuring aerosol concentration and particle size in a model
environment (for example a standard bathroom). Reality-based
mathematical models (e.g., ConsExpo 4.1 (Bremmer et al., 2006a),
BG-Spray (Eickmann, 2007a)) can also be used to quantify aerosol
concentrations over time. While the ideal situation is to have exper-
imental results, the use of exposure models and default values is
sufﬁcient to perform an adequate safety evaluation under routine
conditions.
Data from comprehensive exposure studies as well as from
authorities are available for the most important cosmetic spray
groups – deodorants and hairsprays – such as the COLIPA study
which reviewed use data from 124.100 European households and
more than 32,470 individuals (Hall et al., 2007,2011)  and the Scien-
tiﬁc Committee for Consumer Safety (SCCS, 2010) or the European
Commission (European Commission, 1996). These data can be usedHair spray, pump spray 3.6 Loretz et al. (2006)
a The given numbers represent the total amount leaving the spray dispenser
including the solvent and the propellant used, not taking into account the amount
of  product remaining on the target (e.g., skin/hair).
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Table 2
Parameters for the estimation of the systemic exposure via inhalation.
Parameter Unit
Concentration of the ingredient in the sprayed formulation (C) %
Proportion of non-propellant fraction in the spray (P) %
Amount sprayed per application (A) g
Airborne fraction (AF) %
Distribution volume at time point 1 (V1) m3
Exposure time1 (t1) min
Distribution volume 2 (V2) m3
Exposure time 2 (t2) min
Human breath minute volume (BR) L/min
Mean application(s) per day (DA) 1/d
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tMean body weight (BW) kg
Fraction reaching alveoli, fraction <10 m (RF) %
Default factor substance exchange (G)
n a probabilistic approach. These values can be considered for
ategory-speciﬁc defaults.
Inhalation uptake via the airways may  be estimated from the
oncentration of ingredients in ambient air and human respira-
ory volumes. Only the proportion of the spray that distributes into
he ambient air is in the breathing zone of the consumer and rele-
ant for inhalation exposure. Bremmer et al. assumed that 85% of
prayed hairsprays will end up as intended on the hair and head
Bremmer et al., 2006a). The duration of inhalation exposure may
e assumed to be 10–20 min  in a worst-case scenario. Duration of
xposure is likely much shorter and RIVM (Dutch National Insti-
ute for Public Health and the Environment) quoted an exposure
uration of 5 min  for hair sprays and deodorants (Bremmer et al.,
006a). For hair sprays during the ﬁrst 2 min  post-application, the
pray distributes in a facial/body near cloud of approximate 1–2 m3
round the user. Within the subsequent 18 min, a distribution into a
0 m3 air volume can be assumed. This volume corresponds roughly
o the size of a standard bathroom (Bremmer et al., 2006b).
For a conservative estimate of the Systemic Exposure Dose (SED)
rom a given ingredient of the spray in mg/kg b.w./d the param-
ters described in Table 2 can be applied. In Table 2 as well the
bbreviations used below are explained.
Thus, the substance amount (EA) for relevant exposure may  be
alculated according to the following Eq. (1),  taking into account
he sprayed amount (A), the concentration of the ingredient in the
nal formulation (C), the proportion of non-propellant spray in the
ormulation (P) and the airborne fraction (AF):
A [g] = A [g] × C [%] × P [%] × AF [%] (1)
The potential amount that may  be inhaled during the ﬁrst 2 min
IA1) may  be estimated with the following Eq. (2),  taking into
ccount the breathing rate (BR), distribution volume (V1) at expo-
ure time (t1):
A1 [mg] = (EA [mg]/V1 [l]) × BR [l/ min] × t1 [min] (2)
The potential amount that may  be inhaled during the subse-
uent 18 min  (IA2) may  be estimated using the following Eq. (3),
aking into account the breathing rate, distribution volume (V2) at
xposure time (t2):
A2 [mg] = (EA [mg]/V2 [l]) × BR [l/ min] × t2 [min] (3)
Since a signiﬁcant proportion, assumed as 25%, of the air and
irborne particles are exhaled by the lung without substance
etention, a default factor for substance exchange (G) of 0.75 can
e applied to the exposure calculations (European Commission
uidance Document, 1996).
Only particles with an aerodynamic diameter of less than 10 m
re expected to be respirable and to reach the deep lung (respirable
raction (RF)). As particle sizes from a typical pump spray tend
o be in the range of 70 m (Vielhaber, 1991) they tend to settleters 205 (2011) 97– 104
quickly after spraying thereby reducing their potential to be inhaled
(Eickmann, 2007a).  Upon inhalation, deposition and absorption of
large particles/droplets would occur in the upper airways depend-
ing on their physical chemical properties. Water soluble substances
are expected to be absorbed where deposited. Insoluble larger par-
ticles are eliminated from the respiratory tract by macrophage
entrapment or eliminated via the ciliary-mucosal escalator and
swallowed subsequently. These large particles are not expected to
produce deep lung effects, but may  need to be considered in terms
of oral exposure, local effects and systemic effects upon absorption.
Guidance for estimation of the systemic exposure from the swal-
lowed (non-respirable) fraction can be calculated according to the
European Chemicals Agency (ECHA, 2010).
Given that only a fraction of particles <10 m is relevant for
deep lung exposure and effects, only the percentage of particles
<10 m should be considered for estimates of pulmonary exposure.
Provided that a substance becomes systemically available when
reaching the alveolar region, the systemic exposure dose (SED(inhal))
in [mg/kg/day] may  be calculated with the following Eq. (4) taking
additionally into account the daily application (DA) and the body
weight (BW):
SED(inhal) [mg/kg/d] = (IA1 + IA2 [mg]) × G × RF × DA/BW [kg]
(4)
Total systemic exposure may  be calculated as given in Eq. (5):
SED(tot) = SED(inhal) + SED(dermal) + SED(swallowed) (5)
While above calculations represent a comprehensive and sim-
ple method for exposure estimation, the resulting assessment is
extremely conservative. The particle concentration in ambient air
is assumed to be constant throughout the application and exposure
period, which is an overestimation due to volatilisation, agglomera-
tion and settlement of droplets or particles. Similarly, other factors
that would reduce inhalation exposure, such as product deposi-
tion on the application area and indoor air exchange are not taken
into account. Consequently, the modelling of a spray-generated
exposure is very complicated and requires a precise description
of the application conditions. A realistic assessment of exposure
is always product-speciﬁc, takes into account many different fac-
tors that may  modify exposure conditions and requires complicated
mathematical modelling.
RIVM has developed the software “ConsExpo” which uses
descriptive parameters to estimate consumer exposure to vari-
ous products. The currently available web-based version ConsExpo
4.1 (ConsExpo, Update 2010) includes a mathematical model for
estimation of inhalation exposures. Upon inclusion of basic data
(Bremmer et al., 2006a,b) and speciﬁc product information, the
software is able to generate individual exposure scenarios tak-
ing into account temporal changes of particle concentration in the
ambient air. Table 3 lists the parameters required for exposure
calculations according to ConsExpo.
The software also allows the calculation of the combined der-
mal  and respiratory exposure during the application of cosmetic
sprays, and the estimation of the total systemic exposure to a given
substance as required for a risk assessment.
For the calculation of systemic exposure from sprays, mathe-
matical models from publicly available software packages such as
SprayExpo (Koch et al., 2004), and the model BG-Spray described
by Eickmann (2007a) can be used. The advantages and drawbacks
of the different models have been discussed elsewhere (Eickmann
et al., 2007b).
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Table 3
Data required for consumer exposure estimation using ConsExpo 4.1. software
(Delmaar et al., 2005; Bremmer et al., 2006b).
Parameter Unit
Mean number of applications per day 1/d
Mean body weight kg
Volume of application environment (room) m3
Rate of aeration 1/h
Duration of exposure min
Mass stream of the spray (sprayed amount
per unit time)
g/min
Spraying time min
Spray cloud volume cm3
Height of the application space (room) cm
Airborne fraction %
Weight ratio of the propellant gas %
Weight ratio of solvent %
Weight ratio of non-volatile constituents %
Solvent density g/cm3
3
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CDensity of non-volatile constituents g/cm3
Particle distribution normal or log normal
. Assessing inhalation toxicity
.1. Common ingredients in sprays
The basis of the safety evaluation of cosmetic products is the
omprehensive information on ingredients used, especially their
peciﬁcations and toxicological proﬁles. A number of biologically
ctive ingredients have been restricted by regulations and the use of
ertain substances in sprays, such as dehydroacetic acid, have been
anned in the EU (European Commission, 1976, Annex VI Entry No.
3 EC-Cosmetics-Directive 76/768/EC).
When evaluating the safety of ingredients in sprays from the
nhalation related point of view, the assessor needs to consider
here these compounds may  come into contact with the respi-
atory tract and where possible adverse effects may  occur: e.g.,
ocal irritation of the respiratory tract, systemic effects following
nhalation exposure, respiratory sensitization and local toxicity in
he deep lung. Table 4 lists ingredients typically found in cosmetic
pray products.
For propellant gases and highly volatile solvents, a quantitative
lveolar availability should be assumed. Results from at least one
epeated dose inhalation study should be available to allow the
ssessment of the systemic toxicity and local effects in the respira-
ory tract. As a second option, the systemic load may  be estimated
n the basis of ambient air concentrations and respiratory minute
olume.
The solid compounds in hair sprays are usually polymers. The
ajority of these polymers have low biological reactivity or are
nert (Carthew et al., 2002). However, inhalation of high doses of
nert particles may  produce particle overload of the lung result-
ng in inﬂammatory changes in a dose-dependent manner (Greim
t al., 2001; Muhle and Mangelsdorf, 2003). Absorption and sys-
emic availability of insoluble particles after deep lung exposure is
nlikely. Especially for insoluble particles at a size below 10 m,
nhalation toxicity data is crucial for the safety assessment. Data
able 4
ommon ingredient types used in cosmetic spray products.
Category Examples
Propellant gas Alkanes (propane, butane, t
High volatile solvents Ethanol, isopropanol, cyclo
Low/non-volatile solvents Water or oils (of mineral or
Solids Stabilisation polymers, susp
Fragrance Perfume oils
Formulation constituents Emulsiﬁers, neutralisation 
Active and auxiliary ingredients Stabilisers, cosmetic colourters 205 (2011) 97– 104 101
from a repeated dosing sub-acute, sub-chronic or chronic inhala-
tion study are ideal. If data are limited, extrapolation from studies
on a structurally related and biologically inert chemical may  be
useful. On the basis of such data a safe air concentration based on
experimental data may  be estimated.
Other ingredients in cosmetic sprays are usually present at
low levels so that exposure is likely to be low. Analogous to the
approaches described above, all ingredients need to be evaluated.
Particular attention should be given to potential human inhala-
tion exposure to ﬁne droplets of lipophilic/oily substances, since
such formulations may  produce the so-called “acute respiratory
syndrome” in exposed humans (Vernez et al., 2006).
3.2. Evaluation of potential irritation of the respiratory tract
Mucosal irritation can be caused by reactive chemical species.
Water-soluble and hydrophilic compounds tend to remain in the
mucosa of the upper airways, while more lipophilic and less water-
soluble substances may  penetrate deeper into the lung. Two types
of irritation can be distinguished: a) irritation of nerve endings in
the upper respiratory tract without adverse changes in pulmonary
tissue (sensory irritation) or b) local toxic effects producing local
adverse changes in pulmonary tissue(s). The irritation potential of a
given chemical may  be evaluated based on standardised inhalation
toxicity studies in rodents or by employing mathematical models
which take into consideration known data on lung irritants. Also
in vitro eye or skin irritation tests may  be helpful to evaluate a
potential sensory irritation of the ingredient (Weight-of Evidence
Approach).
In the EU, known respiratory irritants are labelled with the
hazard statement H335 (former risk phrase R37); irritates res-
piratory organs/respiratory irritant (EU Regulation 1272/2008,
European Parliament and Council, 2008; former Council Directive
67/548/EEC). The majority of these chemicals are listed in ChemDat
(Merck Chemie Datenbank, Editor: Merck KGaA, 64271 Darmstadt,
2000) and in TRGS 900 (BAuA, 2006) and carry at least one other
warning label regarding irritation hazard effects on eyes, skin, etc.
(H314, H319, H318, H315; former R34, R35, R36, R41, R38). How-
ever, one may  assume that most substances which are irritant to
the skin or eyes may  also possess a potential being a respiratory
irritant. The new EU Regulation 1272/2008 (Regulation on classiﬁ-
cation, labelling and packaging “CLP Regulation” which is currently
implemented stepwise and which uses a different nomenclature
for risk phrases has to be considered in future. This Regulation is in
line with the UN Globally Harmonized System of Classiﬁcation and
Labelling of Chemicals (quoted in the EU Regulation 1272/2008).
3.3. Systemic toxicity via inhalation exposure
Due to the huge surface area of the lung signiﬁcant systemic
absorption of ingredients are likely, especially when they reach
the alveoli. Gases, vapours and other soluble compounds may
be absorbed across the respiratory mucosa and epithelia upon
contact. Similarly, dissolved solids can reach alveolar regions via
aerosol portions of droplet diameters below 10 m, where they
heir isomers or mixtures), dimethyl ether
methicone
 vegetable origin)
ension agents such as bentonite, aluminum chlorohydrate, inorganic salts
agents, preservatives
ings, complexation agents, derivatives of lanolin, plant extracts, oils
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ay  be absorbed if the suspended solid is soluble or partly sol-
ble in that environment. The total systemic dose of a cosmetic
pray ingredient is calculated from all routes of exposure (see
ection 2.2).
The systemic toxicity of a compound can be identiﬁed from
epeated-dose studies including inhalation, oral and intra venous
tudies. The toxicity data are used to derive safe human doses
ncluding Acceptable Daily Intake (ADI), Reference Doses and occu-
ational exposure limit values. A suitable TTC value or a threshold
alue may  be obtained on the basis of no adverse effect levels or
oncentrations of in vivo experiments (Kroes et al., 2007; Blackburn
t al., 2005).
.4. Respiratory sensitization
Respiratory sensitization is an immunological response that can
esult in a variety of symptoms including rhinitis, conjunctivitis,
heeze, dyspnoea and asthma. There are currently no accepted
nd validated animal models available that can be used to identify
espiratory sensitizing compounds (Boverhof et al., 2008; Pauluhn
nd Mohr, 2005). Rather, information from human exposure (usu-
lly occupational) with or without data from investigational animal
tudies are used to identify sensitizers. In the EU, chemicals
ith known respiratory sensitizing potential are labelled with
he hazard statement H334 (EU Regulation 1272/2008, European
arliament and Council, 2008; former risk phrase R42 (Council
irective 67/548/EEC)). Even if some threshold approaches exist
lso for respiratory sensitizers (Arts et al., 2006; Rijnkels et al., 2008)
t is difﬁcult to quantify dose related effects – so the thresholds
nd the corresponding models are still under development. Res-
iratory allergens include proteins (e.g., enzymes), food extracts
e.g., soy, nuts, wheat) and certain low molecular weight chemicals.
ll known respiratory sensitizers should be limited or reduced to
hreshold below regulated threshold for occupation use (e.g., MAK
r TLV). It should be noted that not for all substances thresholds are
ased on no-effect levels on sensitization and therefore the risk of
ensitization cannot be completely excluded using the thresholds
or occupational use. Especially botanical extracts are popular in
osmetics and their protein content should be limited or eliminated
o reduce risk of allergy in general.
.5. Local toxicity in the deep respiratory tract
Local toxicity in the lower respiratory tract is usually associ-
ted with insoluble particles. For particles, a lung-speciﬁc defence
echanism exists that, under conditions of low or moderate com-
ound load, prevents insult to the organ and the organism. Particles
re taken up by lung macrophages that internalize and/or break
own particles by phagocytosis. Macrophages thus clear the lung
f inhaled particles by removing them from further interaction with
ung tissue. Due to the relatively limited capacity of macrophage-
ediated clearance of insoluble inhaled particles, exposure to
tmospheres containing very high concentrations of particulate
atter may  result in overload and at least in chronic damage.
 widely accepted hypothesis suggests that the mechanism is
ue to an immobilisation of alveolar macrophages following pro-
onged excessive phagocytosis (Oberdörster, 2002; Pauluhn, 2009).
ccording to current scientiﬁc knowledge, this phenomenon of
pulmonary overload” leads to chronic inﬂammation, ﬁbrosis and,
nder conditions of long-term exposure to the noxious agent, may
e involved in lung tumour formation.
The rat is known to be more susceptible to lung overload than
rimates (Mauderly, 1997) so the question of maximal safe load
f human lungs with alveolarly available inert ﬁne and ultraﬁne
articles has been the subject of intensive discussions (ILSI, Risk
cience Institute, 2000). The general particle dust threshold forters 205 (2011) 97– 104
occupation use is 1.5 mg/m3applies EU-wide for the alveolar frac-
tion (<10 m)  and 4 mg/m3 for the inhalable fraction (>10 m),
derived from inhalation toxicity studies in the rat (Commission
for the Investigation of Health Hazards of Chemical Compounds
in the Work Area, 2010). This inert dust threshold value for the
alveolar fraction of granular biopersistent dust might be consid-
erably lowered in the near future. These thresholds cover short
term exposures of 8 h, compared to EU air quality standards for
ﬁne dust, which is intended to be the mean over a one year period.
Since the exposure to cosmetic spray products occurs only over
a signiﬁcantly shorter time frame of several minutes, the occu-
pational ﬁne dust thresholds must be seen as conservative, but
useful tool to avoid local particle overload of the deeper lung.
Furthermore, this threshold value can be viewed as conservative,
because of the above-mentioned sensitivity of the chosen animal
species.
4. Safety and risk assessment
In the safety assessment, the exposure of the consumer is gen-
erally compared to a concentration or dose causing no effect in a
relevant in vivo experiment. For inhalation, the key parameter is
the No Observed Effect Concentration (NOEC), i.e. the substance
concentration in ambient (breathable) air that produces no toxi-
cological effect. The NOEC is mainly used for the approximation
of local tolerance endpoints like irritation in the respiratory tract.
The No Observed Effect Level (NOEL) or No Observed Adverse Effect
Level (NOAEL) is the highest experimental dose at which there are
no statistically or biologically signiﬁcant increases in the frequency
or severity of effects seen in the exposed population, compared
with an appropriate unexposed population (Derelanko, 2000a).
Occasionally, terms like “mass percentage” and “number of parti-
cles” are used but not recommended for the evaluation of potential
spray effects. To directly compare the exposure data with animal
study results, it is most practical to provide the concentration in
%mass. As the use of mass percentage and not particle numbers
is common practice in existing inhalation studies (see OECD TG
412/413), this parameter of particle number is not a practical tool
in risk assessment. The mass percentage can be determined in stan-
dardised methods of measurement, and thus allows a direct 1:1
comparison. Therefore, in the present document, calculations are
based on mass percentage data.
However, a relationship between the particle surface and tox-
icity is under discussion but not understood quantitatively at the
moment.
To estimate the risk of systemic toxicity, the Systemic Expo-
sure Dose can be compared to the NOEL or NOAEL obtained from a
suitable in vivo study, such as a repeated-dose inhalation study. The
assessor may  consider data from repeated-dose oral or intravenous
studies but there are concerns regarding route to route extrapola-
tion so additional guidance (European Chemicals Agency (ECHA),
2008) and judgement is needed. When extrapolating from in vivo
studies the assessor also needs to consider differences between ani-
mal  species (usually rat) used in the in vivo studies and humans. The
anatomy and physiology of the airway of rodents are signiﬁcantly
different from the human respiratory tract (ECHA, 2008, Table R.8-
2), leading to an increased deposition of particles in the upper
respiratory tract (US EPA, 1997). The relative lung surface area par-
ticipating in oxygen exchange in the rat is much larger than in man
(Carthew et al., 2002). For human adults (60 kg), the respiratory
minute volume during light physical work is generally assumed
to be approximately 13 L/min or 20 m3/day (Finley et al., 1994).
The breathing minute volume of rats in relation to body weight
is approximately 4.4-fold higher than that of humans (Derelanko,
2000b).
gy Let
M
e
i
i
i
o
l
f
i
f
v
s
b
n
p
8
t
r
s
T
B
W
r
a
e
a
i
m
5
a
a
n
u
s
a
a
w
a
p
m
r
r
E
C
e
s
L
a
A
d
a
(
tH. Rothe et al. / Toxicolo
Today’s risk assessment schemes rely on a Margin of Safety or
argin of Exposure calculation that compares the human systemic
xposure dose with a NO(A)EL in an appropriate animal model.
The MoS/MoE should be at least 100 for systemic effect (includ-
ng dermal and oral exposure) and 25-fold for local lung effects
n order to safeguard consumer safety, based on a default of 2.5 for
nterspecies and 10 for intra-species differences (ECHA, 2008). Lists
f maximum air levels for a variety of substances have been pub-
ished by the German MAK-Commission (MAK values, Commission
or the Investigation of Health Hazards of Chemical Compounds
n the Work Area (MAK  commission, 2010)) or the American Con-
erence of Governmental Industrial Hygienists (TLV values). MAK
alues (maximum workplace concentrations) essentially corre-
pond to TLVs (threshold limit values). MAK- or TLV-values may
e used as a basis of risk assessment. However, here it should be
oted that MAK- or TLV-values have been developed in order to
rotect healthy adult workers who are occupationally exposed for
 h/day and a 5 day working week. This is an important difference
o the general population exposed to cosmetic products. For impu-
ities that occur at very low levels in sprays, a risk assessment for
ystemic toxicity can be based on the concept of the Threshold of
oxicological Concern (Kroes et al., 2007; Drew and Fraggos, 2007;
lackburn et al., 2005; Carthew et al., 2009; Escher et al., 2010).
hile there is no generally accepted TTC of local effects in the
espiratory tract, TTC values for systemic toxicity may be applied
nd after modiﬁcation take into account for route to route differ-
nces between the respiratory tract and other organ systems (e.g.,
bsorption, metabolism). However, so far adequate TTC models for
nhalation route are under development (Carthew et al., 2009) and
ay  become relevant in future.
. Conclusion
The described common principles can be applied to safety
ssessment of cosmetic sprays based on classical elements of risk
ssessment. The approach described relies on understanding exter-
al, systemic and in particular respiratory tract exposure and dose,
nderstanding assessing potential toxicities and determination of
afe exposure levels. The safety assessors will beneﬁt from having
ccess to improved exposure models and to standardized safety
ssessment methodologies utilized for spray product evaluation
ithout interfering with the ﬂexibility of the individual safety
ssessors who are responsible for the safety of their products. This
aper is intended to provide basic elements of a tiered safety assess-
ent approach in order to increase transparency for regulators and
eliability of results to the beneﬁt of the consumer. It provides a
ecommendation to use these tools in the sense of a Weight-of-
vidence Approach when conducting the safety assessment.
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